% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Oster:284612,
      author       = {C. Oster$^*$ and T. Schmidt$^*$ and S. Agkatsev$^*$ and L.
                      Lazaridis$^*$ and C. Kleinschnitz and U. Sure$^*$ and B.
                      Scheffler$^*$ and S. Kebir$^*$ and M. Glas$^*$},
      title        = {{A}re we providing best-available care to newly diagnosed
                      glioblastoma patients? {S}ystematic review of phase {III}
                      trials in newly diagnosed glioblastoma 2005-2022.},
      journal      = {Neuro-oncology advances},
      volume       = {5},
      number       = {1},
      issn         = {2632-2498},
      address      = {Oxford},
      publisher    = {Oxford University Press},
      reportid     = {DKFZ-2023-02031},
      pages        = {1-14},
      year         = {2023},
      abstract     = {Glioblastoma is the most aggressive primary brain cancer
                      with a poor prognosis. Despite numerous studies in the past
                      17 years, effective treatment options for glioblastoma
                      remain limited. In this study, we aimed to identify and
                      compare phase III clinical trials for glioblastoma in terms
                      of efficacy and baseline characteristics.A systematic
                      literature search was conducted using PubMed and
                      ClinicalTrials.gov to identify phase III clinical trials for
                      glioblastoma in adult patients. The target population
                      included adult patients aged 18 years and above (younger
                      cohort) and patients ≥60 years of age (elderly cohort).
                      The search results were screened based on predefined
                      inclusion criteria, and the included trials were analyzed
                      for their study design, baseline characteristics, and
                      survival results.Eleven trials met the inclusion criteria in
                      the younger cohort. Of these, three reported a statistically
                      significant improvement in overall survival (OS), including
                      the EORTC/NCIC study (NCT00006353), EF-14 (NCT00916409), and
                      CeTeG (NCT01149109). Of the 11 trials, eight were open-label
                      randomized trials, including all of the positive ones, while
                      three negative trials employed treatment blinding and a
                      placebo control. The baseline characteristics of the trials
                      [such as extent of resection, age, gender, and
                      O(6)-methylguanine-DNA-methyltransferase (MGMT) promoter
                      methylation status] did not significantly differ between
                      positive and negative trials. Isocitrate dehydrogenase (IDH)
                      mutation status was analyzed in only two trials, with a
                      small percentage of IDH-mutated tumors in each.
                      Additionally, three more trials in the elderly cohort showed
                      a statistically significant improvement of OS, the NOA-08
                      trial, the ISRCTN81470623-trial by Malmström et al. and
                      NCT00482677-trial by Perry et al. Their baseline
                      characteristics and implications are also analyzed.This
                      analysis of phase III clinical trials for glioblastoma
                      conducted since 2005 showed that the majority of trials did
                      not result in a significant improvement in OS. Among the
                      trials included in this analysis, only the EORTC/NCIC,
                      EF-14, and CeTeG studies demonstrated a positive OS outcome
                      in the younger cohort.},
      subtyp        = {Review Article},
      keywords     = {CeTeG (Other) / EF-14 (Other) / glioblastoma (Other) /
                      meta-analysis (Other) / phase III trials (Other)},
      cin          = {ED01},
      ddc          = {610},
      cid          = {I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37811538},
      pmc          = {pmc:PMC10558397},
      doi          = {10.1093/noajnl/vdad105},
      url          = {https://inrepo02.dkfz.de/record/284612},
}